Levofloxacin Noridem Enterprises (Levofloxacin)

Levofloxacin inhibits the bacterial enzymes DNA gyrase and topoisomerase IV, which are essential for DNA supercoiling and separation during replication and transcription. By blocking these targets, the drug exerts a bactericidal effect against a broad range of Gram‑negative and Gram‑positive organisms.

The dosage and duration are determined by the prescribing clinician based on the type and severity of infection, patient weight, renal function, and other clinical factors. Healthcare professionals adjust the regimen to achieve optimal therapeutic outcomes while minimizing toxicity.

Safety data for levofloxacin during pregnancy and lactation are limited, and the product carries an unknown pregnancy category. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and the necessary import documentation.

Levofloxacin offers a broad spectrum of activity similar to other fluoroquinolones but provides higher bioavailability and tissue penetration, especially in respiratory and urinary tissues. Compared with agents such as ciprofloxacin, it often requires once‑daily dosing and may have a more favorable safety profile for certain patient groups, though class‑related risks remain.

Levofloxacin Noridem Enterprises should be stored at ambient temperature, preferably below 25 °C. Keep the vials in their original packaging, protect them from moisture and direct light, and avoid freezing. Follow standard aseptic techniques when preparing the solution for intravenous administration.

The product is supplied as an injectable solution for intravenous infusion. Administration is performed by a qualified healthcare professional, typically over a short infusion period as directed by the prescriber. The infusion rate and dilution volume are determined based on the specific clinical protocol.

Serious adverse events include tendon rupture (especially Achilles tendon), QT‑interval prolongation leading to cardiac arrhythmias, and severe hypersensitivity reactions such as anaphylaxis or angioedema. Patients should be monitored for musculoskeletal pain, cardiac symptoms, or signs of allergic reaction during therapy.

Levofloxacin is contraindicated in individuals with a known hypersensitivity to levofloxacin or other fluoroquinolones, those with a history of tendon disorders related to fluoroquinolone use, and patients taking medications that significantly prolong the QT interval. Caution is also advised for pregnant or breastfeeding women, and for patients with severe renal impairment unless dose‑adjusted.